Mizuho Lowers PT on Elevance Health (ELV), Keeps a Buy Rating

Elevance Health, Inc. (NYSE:ELV) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 11, Mizuho analyst Ann Hynes lowered the firm’s price target on Elevance Health, Inc. (NYSE:ELV) from $413 to $350 and maintained a Buy rating on the stock. ​The analyst noted that the reduced price target reflects the company’s reaffirmed guidance amid the ongoing Centers for Medicare and Medicaid Services scrutiny. Hynes said in a research note that the company disclosed that the Cente ...